ALLMedicine™ Hodgkin Lymphoma Center
Research & Reviews 7,417 results
https://doi.org/10.1002/ijc.34180
International Journal of Cancer; Yarmolinsky J, Amos CI et. al.
Jun 25th, 2022 - Deucravacitinib, a novel, selective inhibitor of TYK2 is currently under review at the FDA and EMA for treatment of moderate-to-severe plaque psoriasis. It is unclear whether recent safety concerns (ie, elevated rates of lung cancer and lymphoma) ...
https://clinicaltrials.gov/ct2/show/NCT03739827
Jun 24th, 2022 - Background: Rare tumors are defined as fewer than 150 incident cases per one million per year. Consequently, only 11 tumor types are common in U.S. adults (prostate, breast, lung/bronchus, colon, uterus, bladder, melanoma, rectum, ovary, non-Hodgk...
https://clinicaltrials.gov/ct2/show/NCT03484702
Jun 24th, 2022 - This is a study to determine the efficacy and safety of JCAR017 in adult participants with aggressive B-cell NHL. The study will enroll participants in Europe and Japan with diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS; de no...
https://clinicaltrials.gov/ct2/show/NCT00967785
Jun 24th, 2022 - Mozobil (TM) (plerixafor injection, Genzyme/Sanofi) is a Food and Drug Administration approved medication to mobilize CD34+ hematopoietic stem cells prior to apheresis and use in autologous transplantation in non-Hodgkin lymphoma and multiple myel...
https://clinicaltrials.gov/ct2/show/NCT04739813
Jun 24th, 2022 - Background: Combination chemotherapy with rituximab has been the mainstay of treatment for CD20-positive B-cell lymphomas. Significant advances have been made in curing aggressive B-cell lymphomas with chemoimmunotherapy, but indolent lymphomas an...
Guidelines 17 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894347
British Journal of Haematology; Turton P, El-Sharkawi D et. al.
Nov 23rd, 2020 - Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants and new breast sy...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723685
Journal of Clinical Oncology : Official Journal of the Am... Mulder RL, Hudson MM et. al.
Oct 21st, 2020 - As new evidence is available, the International Late Effects of Childhood Cancer Guideline Harmonization Group has updated breast cancer surveillance recommendations for female survivors of childhood, adolescent, and young adult cancer. We used ev...
https://doi.org/10.6004/jnccn.2020.0036
Journal of the National Comprehensive Cancer Network : JN... Davies K, Barth M et. al.
Aug 7th, 2020 - Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the tre...
https://doi.org/10.1093/annonc/mdy080
Annals of Oncology : Official Journal of the European Soc... Eichenauer DA, Aleman BMP et. al.
Oct 1st, 2018 - Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2018|Eichenauer DA,Aleman BMP,André M,Federico M,Hutchings M,|diagnosis,epidemiology,therapy,standards,
https://doi.org/10.6004/jnccn.2018.0066
Journal of the National Comprehensive Cancer Network : JN... Reid E, Suneja G et. al.
Aug 14th, 2018 - People living with HIV (PLWH) are diagnosed with cancer at an increased rate over the general population and generally have a higher mortality due to delayed diagnoses, advanced cancer stage, comorbidities, immunosuppression, and cancer treatment ...
Drugs 64 results see all →
Clinicaltrials.gov 862 results
https://clinicaltrials.gov/ct2/show/NCT03739827
Jun 24th, 2022 - Background: Rare tumors are defined as fewer than 150 incident cases per one million per year. Consequently, only 11 tumor types are common in U.S. adults (prostate, breast, lung/bronchus, colon, uterus, bladder, melanoma, rectum, ovary, non-Hodgk...
https://clinicaltrials.gov/ct2/show/NCT03484702
Jun 24th, 2022 - This is a study to determine the efficacy and safety of JCAR017 in adult participants with aggressive B-cell NHL. The study will enroll participants in Europe and Japan with diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS; de no...
https://clinicaltrials.gov/ct2/show/NCT00967785
Jun 24th, 2022 - Mozobil (TM) (plerixafor injection, Genzyme/Sanofi) is a Food and Drug Administration approved medication to mobilize CD34+ hematopoietic stem cells prior to apheresis and use in autologous transplantation in non-Hodgkin lymphoma and multiple myel...
https://clinicaltrials.gov/ct2/show/NCT04739813
Jun 24th, 2022 - Background: Combination chemotherapy with rituximab has been the mainstay of treatment for CD20-positive B-cell lymphomas. Significant advances have been made in curing aggressive B-cell lymphomas with chemoimmunotherapy, but indolent lymphomas an...
https://clinicaltrials.gov/ct2/show/NCT05371054
Jun 24th, 2022 - Background: High unmet medical need for relapsed/refractory non-Hodgkin lymphoma (NHL) after exhausting chemotherapy and/or chemo-immunotherapy regimens Targeted therapies aimed at disrupting cell death pathway in hematologic malignancies are emer...
News 1,409 results
https://www.medscape.com/viewarticle/975410
Jun 10th, 2022 - Patients with advanced classical Hodgkin lymphoma treated with first line brentuximab vedotin (Adcetris) plus chemotherapy showed substantial improvements in overall survival compared with those receiving standard chemotherapy, new research shows....
https://www.mdedge.com/hematology-oncology/article/255210/gene-therapy/exciting-new-gene-therapy-yields-promising-results
Heidi Splete
Jun 5th, 2022 - Patients with relapsed or refractory B cell non-Hodgkin lymphoma responded positively to a new therapy based on genome editing in early results from a phase 1 study, according to a news release from manufacturer Caribou Biosciences. In the first-i.
https://www.onclive.com/view/ublituximab-umbralisib-bla-snda-in-cll-and-sll-voluntarily-withdrawn
May 6th, 2022 - The pending biologics license application (BLA) and supplemental new drug application (sNDA) seeking the approval of the combination of ublituximab and umbralisib (Ukoniq; U2) in adult patients with chronic lymphocytic leukemia (CLL) and small lym...
https://www.medscape.com/viewarticle/973396
May 4th, 2022 - The persistent shortage of dacarbazine has led to an "acute and unprecedented crisis" in the treatment of patients with advanced classical Hodgkin lymphoma, experts say. Dacarbazine, an essential part of the four-drug standard of care for managing...
https://www.onclive.com/view/dr-westin-on-the-evolving-landscape-of-car-t-cell-therapy-in-nhl
May 3rd, 2022 - Jason R. Westin, MD, director, Lymphoma Clinical Research, section chief, Aggressive Lymphoma, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the evolv...